{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:52:19Z","timestamp":1765889539749,"version":"build-2065373602"},"reference-count":76,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Metastatic non-small cell lung cancer (mNSCLC) contributes to the economic burden. Over the past decade, treatment has evolved with the introduction of epidermal growth factor receptor (EGFR) anaplastic lymphoma kinase (ALK)-targeted, and immune-oncology (IO) drugs. However, limited evidence exists on the long-term costs of mNSCLC treatments in Sweden.\nPatient\/material and methods: This population-based retrospective study used data from the National Board of Health and Welfare, identifying patients initially diagnosed with stage IV NSCLC between 2011 and 2020. Healthcare costs, including inpatient care, outpatient care, and drug expenses, were assessed using Diagnosis-Related Group (DRG) tariffs and prescription data. Drug expenses exceeding DRG tariff limits, such as IO drugs, were calculated separately based on retail list prices. Costs were analyzed over 5 years post-diagnosis and adjusted to 2023 values.\nResults: A total of 17,107 patients were included. IO drug use increased sharply after 2016, becoming the predominant therapy. EGFR- and ALK-targeted drug use steadily increased. Overall costs rose over time, especially in the first year after diagnosis. The first-year mean cost was highest among patients receiving IO drugs (\u20ac105,286), primarily due to drug acquisition, but declined in subsequent years. ALK- and EGFR-targeted therapies also had high initial costs but remained stable thereafter.\nInterpretation: This study highlights the increasing economic burden of mNSCLC treatment in Sweden, driven by the targeted and IO drugs. While ALK-, EGFR-targeted, and IO drugs contribute to high first-year mean costs, IO drug costs decline significantly in subsequent years after diagnosis.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.44650","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:28:27Z","timestamp":1761542907000},"page":"1473-1481","source":"Crossref","is-referenced-by-count":1,"title":["Cost of treatment of metastatic non-small lung cancer in Sweden, 2011\u20132023"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-3325","authenticated-orcid":false,"given":"Kun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0980-8965","authenticated-orcid":false,"given":"Michael","family":"Sweeting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Wilking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5751-6292","authenticated-orcid":false,"given":"Linus Mattias","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,10,26]]},"reference":[{"unstructured":"Socialstyrelsen. Statistical database, cancer [Internet]. 2024. [accessed in September, 2024] Available from: https:\/\/www.socialstyrelsen.se","key":"130884"},{"doi-asserted-by":"crossref","unstructured":"Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165\u201374.","key":"130885","DOI":"10.1016\/S1470-2045(13)70442-X"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(13)70442-X","key":"130886","DOI":"10.1016\/S1470-2045(13)70442-X"},{"unstructured":"Cancer Research UK. Lung cancer UK price tag eclipses the cost of any other cancer. 2012, Cancer Research UK, London.","key":"130887"},{"doi-asserted-by":"crossref","unstructured":"Hofmarcher T, Lindgren P, Wilking N, J\u00f6nsson B. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41\u20139.","key":"130888","DOI":"10.1016\/j.ejca.2020.01.011"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.011","key":"130889","DOI":"10.1016\/j.ejca.2020.01.011"},{"doi-asserted-by":"crossref","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357.","key":"130890","DOI":"10.1056\/NEJMoa0810699"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa0810699","key":"130891","DOI":"10.1056\/NEJMoa0810699"},{"doi-asserted-by":"crossref","unstructured":"Bollinger MK, Agnew AS, Mascara GP. Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2018;24(5):379\u201388.","key":"130892","DOI":"10.1177\/1078155217712401"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1078155217712401","key":"130893","DOI":"10.1177\/1078155217712401"},{"doi-asserted-by":"crossref","unstructured":"Rothschild SI, Gautschi O. Crizotinib in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2013;14(5):473\u201380.","key":"130894","DOI":"10.1016\/j.cllc.2013.04.006"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.cllc.2013.04.006","key":"130895","DOI":"10.1016\/j.cllc.2013.04.006"},{"doi-asserted-by":"crossref","unstructured":"Ryser CO, Diebold J, Gautschi O. Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives. Curr Opin Oncol. 2019;31(1):8\u201312.","key":"130896","DOI":"10.1097\/CCO.0000000000000494"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/CCO.0000000000000494","key":"130897","DOI":"10.1097\/CCO.0000000000000494"},{"unstructured":"Midha A, Dearden SMc, Cormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892\u2013911.","key":"130898"},{"doi-asserted-by":"crossref","unstructured":"Addeo A, Tabb\u00f2 F, Robinson T, Buffoni L, Novello S. Precision medicine in ALK rearranged NSCLC: a rapidly evolving scenario. Crit Rev Oncol Hematol. 2018;122:150\u20136.","key":"130899","DOI":"10.1016\/j.critrevonc.2017.12.015"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.12.015","key":"130900","DOI":"10.1016\/j.critrevonc.2017.12.015"},{"doi-asserted-by":"crossref","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","key":"130901","DOI":"10.1056\/NEJMoa1504627"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1504627","key":"130902","DOI":"10.1056\/NEJMoa1504627"},{"doi-asserted-by":"crossref","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","key":"130903","DOI":"10.1056\/NEJMoa1606774"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1606774","key":"130904","DOI":"10.1056\/NEJMoa1606774"},{"doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Gonz\u00e1lez J, Ruiz-Ba\u00f1obre J, Afonso-Afonso FJ, Amenedo-Gancedo M, Areses-Manrique MDC, Campos-Balea B, et al. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: a pairwise meta-analysis. J Clin Med. 2020;9(7):2093.","key":"130905","DOI":"10.3390\/jcm9072093"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm9072093","key":"130906","DOI":"10.3390\/jcm9072093"},{"unstructured":"The Dental and Pharmaceutical Benefits Agency, TLV_3331_2016: Underlag f\u00f6r beslut i landstingen \u2013 Keytruda (pembrolizumab), Keytruda som monoterapi \u00e4r indicerat som f\u00f6rsta linjens behandling av metastaserad icke-sm\u00e5cellig lungcancer (NSCLC) hos vuxna vars tum\u00f6rer uttrycker PD-L1 i \u2265 50 % av tum\u00f6rcellerna (tumour proportion score (TPS) \u2265 50 %) och som inte \u00e4r positiva f\u00f6r mutationer i EGFR eller ALK. Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV); 2017, Stockholm.","key":"130907"},{"unstructured":"The Dental and Pharmaceutical Benefits Agency, TLV_875_2016: Underlag f\u00f6r beslut i landstingen \u2013 Opdivo (nivolumab) f\u00f6r behandling av vuxna med lokalt avancerad eller metastaserande icke-sm\u00e5cellig lungcancer (NSCLC) av icke-skivepiteltyp efter tidigare kemoterapi. Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV); 2016, Stockholm.","key":"130908"},{"unstructured":"The Dental and Pharmaceutical Benefits Agency, TLV_1166_2016: Underlag f\u00f6r beslut i landstingen \u2013 Keytruda (pembrolizumab) f\u00f6r behandling av lokalt avancerad eller metastaserad PD L1-positiv icke-sm\u00e5cellig lungcancer (NSCLC) hos vuxna som tidigare behandlats med \u00e5tminstone en kemoterapiregim. Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV); 2016, Stockholm.","key":"130909"},{"unstructured":"The Dental and Pharmaceutical Benefits Agency, TLV_2395_2016: Underlag f\u00f6r beslut i landstingen \u2013 Tecentriq (atezolizumab) f\u00f6r behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-sm\u00e5cellig lungcancer (NSCLC) efter tidigare behandling med kemoterapi. Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV); 2018, Stockholm.","key":"130910"},{"unstructured":"The Dental and Pharmaceutical Benefits Agency, TLV_2440_2019: Underlag f\u00f6r beslut i landstingen \u2013 Tecentriq (atezolizumab) i kombination med karboplatin och etoposid \u00e4r indicerat f\u00f6r f\u00f6rsta linjens behand ling av vuxna patienter med utbredd sm\u00e5cellig lungcancer (ES-SCLC). Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV); 2019, Stockholm.","key":"130911"},{"unstructured":"The Dental and Pharmaceutical Benefits Agency, TLV_4226_2014: Underlag f\u00f6r beslut i landstingen \u2013 Opdivo (nivolumab) f\u00f6r att behandla vuxna patienter med en avancerad form av lungcancer som spridit sig eller vuxit trots tidigare behandling med kemoterapi. Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV); 2015, Stockholm.","key":"130912"},{"doi-asserted-by":"crossref","unstructured":"Gouliaev A, Rasmussen TR, Malila N, Fjellbirkeland L, L\u00f6fling L, Jakobsen E, et al. Lung cancer registries in Denmark, Finland, Norway and Sweden: a comparison and proposal for harmonization. Acta Oncol. 2023;62(1):1\u20137.","key":"130913","DOI":"10.1080\/0284186X.2023.2172687"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2023.2172687","key":"130914","DOI":"10.1080\/0284186X.2023.2172687"},{"unstructured":"Socialstyrelsen. Viktlistor f\u00f6r NordDRG [Interenet]. [accessed in Setember, 2024] Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/klassifikationer-och-koder\/drg\/viktlistor\/.","key":"130915"},{"doi-asserted-by":"crossref","unstructured":"Busse R, Geissler A, Aaviksoo A, Cots F, H\u00e4kkinen U, Kobel C, et al. Diagnosis related groups in Europe: moving towards transparency, efficiency, and quality in hospitals? BMJ. 2013;346:f3197.","key":"130916","DOI":"10.1136\/bmj.f3197"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.f3197","key":"130917","DOI":"10.1136\/bmj.f3197"},{"doi-asserted-by":"crossref","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The Phase III POSEIDON study. J Clin Oncol. 2023;41(6):1213\u201327.","key":"130918","DOI":"10.1200\/JCO.22.00975"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.22.00975","key":"130919","DOI":"10.1200\/JCO.22.00975"},{"doi-asserted-by":"crossref","unstructured":"Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2013positive, advanced non\u2013small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol. 2020;38(14):1580\u201390.","key":"130920","DOI":"10.1200\/JCO.19.02446"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.19.02446","key":"130921","DOI":"10.1200\/JCO.19.02446"},{"unstructured":"European Medicines Agency, Summary of Product Characteristics. Opdivo in combination with ipilimumab in non-small cell lung cancer. European Medicines Agency, Amsterdam.","key":"130922"},{"doi-asserted-by":"crossref","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192\u2013237.","key":"130923","DOI":"10.1093\/annonc\/mdy275"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdy275","key":"130924","DOI":"10.1093\/annonc\/mdy275"},{"doi-asserted-by":"crossref","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>&#x2606;<\/sup>. Ann Oncol. 2023;34(4):339\u201357.","key":"130925","DOI":"10.1016\/j.annonc.2022.12.009"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009","key":"130926","DOI":"10.1016\/j.annonc.2022.12.009"},{"unstructured":"Official Statistics of Sweden. Consumer Price Index (CPI) [Internet]. [accessed in September, 2024] Available from: https:\/\/www.scb.se","key":"130927"},{"unstructured":"European Central Bank, ECB statistics, Swedish Krona (SEK). Average from 2 January 2023 to 29 December 2023 [Internet]. [accessed in September, 2024] Available from: https:\/\/www.ecb.europa.eu","key":"130928"},{"doi-asserted-by":"crossref","unstructured":"Li FDong X. Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: the 5-year outcomes of the KEYNOTE-024 trial. Thorac Cancer. 2021;12(23):3085\u20137.","key":"130929","DOI":"10.1111\/1759-7714.14193"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1759-7714.14193","key":"130930","DOI":"10.1111\/1759-7714.14193"},{"doi-asserted-by":"crossref","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","key":"130931","DOI":"10.1056\/NEJMoa1801005"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1801005","key":"130932","DOI":"10.1056\/NEJMoa1801005"},{"doi-asserted-by":"crossref","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351.","key":"130933","DOI":"10.1056\/NEJMoa1810865"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1810865","key":"130934","DOI":"10.1056\/NEJMoa1810865"},{"doi-asserted-by":"crossref","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):Jco2001605.","key":"130935","DOI":"10.1200\/JCO.20.01605"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.20.01605","key":"130936","DOI":"10.1200\/JCO.20.01605"},{"doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lee J-S, Ciuleanu T-E, Caro RB, Nishio M, Urban L, et al., Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non\u2013small cell lung cancer (NSCLC): results from CheckMate 227. 2022;40(17_suppl):LBA9025.","key":"130937","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9025"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2022.40.17_suppl.LBA9025","key":"130938","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9025"},{"doi-asserted-by":"crossref","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al., Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","key":"130939","DOI":"10.1056\/NEJMoa1913662"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1913662","key":"130940","DOI":"10.1056\/NEJMoa1913662"},{"doi-asserted-by":"crossref","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JC-H, Yanagitani N, Kim S-W, et al. Osimertinib with or without chemotherapy in <i>EGFR<\/i>-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","key":"130941","DOI":"10.1056\/NEJMoa2306434"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2306434","key":"130942","DOI":"10.1056\/NEJMoa2306434"},{"doi-asserted-by":"crossref","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al., Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056\u201364.","key":"130943","DOI":"10.1016\/j.annonc.2020.04.478"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2020.04.478","key":"130944","DOI":"10.1016\/j.annonc.2020.04.478"},{"doi-asserted-by":"crossref","unstructured":"Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al., Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the Phase III CROWN study. J Clin Oncol. 2024;42(29):3400\u20139.","key":"130945","DOI":"10.1200\/JCO.24.00581"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.24.00581","key":"130946","DOI":"10.1200\/JCO.24.00581"},{"doi-asserted-by":"crossref","unstructured":"Leskel\u00e4 RL, Korhonen S, Haavisto I, Nuutinen M, Peltonen E, Herse F, et al., Trends in cost of treatment of lung cancer patients in 2014\u20132019 in Finland \u2013 a descriptive register study. Acta Oncol. 2023;62(6):587\u201393.","key":"130947","DOI":"10.1080\/0284186X.2023.2218040"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2023.2218040","key":"130948","DOI":"10.1080\/0284186X.2023.2218040"},{"unstructured":"Manzano A, Svedman C, Hofmarcher T, Wilking N. Comparator report on cancer in Europe 2025 \u2013 disease burden, costs and access to medicines and molecular diagnostics [Internet]. Available from: https:\/\/ihe.se\/en\/rapport","key":"130949"},{"doi-asserted-by":"crossref","unstructured":"Gouliaev A, Risikesan J, Christensen NL, Rasmussen TR, Hilberg O, Ibsen R, et al. Direct and indirect economic burden of lung cancer in Denmark a nationwide study. Eur Clin Respir J. 2021;8(1):1951963.","key":"130950","DOI":"10.1080\/20018525.2021.1951963"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/20018525.2021.1951963","key":"130951","DOI":"10.1080\/20018525.2021.1951963"},{"doi-asserted-by":"crossref","unstructured":"Bugge C, S\u00e6ther EM, Brustugun OT, Kristiansen IS. Societal cost of cancer in Norway \u2013results of taking a broader cost perspective. Health Policy. 2021;125(8):1100\u20137.","key":"130952","DOI":"10.1016\/j.healthpol.2021.05.008"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.healthpol.2021.05.008","key":"130953","DOI":"10.1016\/j.healthpol.2021.05.008"},{"unstructured":"The Dental and Pharmaceutical Benefits Agency. International price comparison 2023, an analysis of Swedish pharmaceutical prices in relation to 19 other European countries [Internet]. 2023. Available from: https:\/\/www.tlv.se","key":"130954"},{"unstructured":"Sveriges Kommuner och Regioner. Regionernas samverkansmodell f\u00f6r l\u00e4kemedel, Avtal [Internet]. Available from: https:\/\/samverkanlakemedel.se","key":"130955"},{"doi-asserted-by":"crossref","unstructured":"Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. S Med Rev. 2012;5(1):38\u201346.","key":"130956","DOI":"10.2174\/1876824501305010001"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2174\/1876824501305010001","key":"130957","DOI":"10.2174\/1876824501305010001"},{"doi-asserted-by":"crossref","unstructured":"Bergqvist J, Ljunggren G. The impact of integrated home palliative care services on resource use and place of death. J Palliat Med. 2020;23(1):67\u201373.","key":"130958","DOI":"10.1089\/jpm.2018.0639"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1089\/jpm.2018.0639","key":"130959","DOI":"10.1089\/jpm.2018.0639"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44650\/51833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44650\/51833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:28:58Z","timestamp":1761542938000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/44650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":76,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.44650","relation":{},"ISSN":["1651-226X"],"issn-type":[{"type":"electronic","value":"1651-226X"}],"subject":[],"published":{"date-parts":[[2025,10,26]]}}}